| Literature DB >> 21029525 |
Stanislas Rebaudet1, Hervé Bogreau, Rahamatou Silaï, Jean François Lepere, Lionel Bertaux, Bruno Pradines, Jean Delmont, Philippe Gautret, Philippe Parola, Christophe Rogier.
Abstract
The efficacy of malaria control and elimination on islands may depend on the intensity of new parasite inflow. On the Comoros archipelago, where falciparum malaria remains a major public health problem because of spread of drug resistance and insufficient malaria control, recent interventions for malaria elimination were planned on Moheli, 1 of 4 islands in the Comoros archipelago. To assess the relevance of such a local strategy, we performed a population genetics analysis by using multilocus microsatellite and resistance genotyping of Plasmodium falciparum sampled from each island of the archipelago. We found a contrasted population genetic structure explained by geographic isolation, human migration, malaria transmission, and drug selective pressure. Our findings suggest that malaria elimination interventions should be implemented simultaneously on the entire archipelago rather than restricted to 1 island and demonstrate the necessity for specific chemoresistance surveillance on each of the 4 Comorian islands.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21029525 PMCID: PMC3294527 DOI: 10.3201/eid1611.100694
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Epidemiologic and sampling characteristics of 5 sites studied for Plasmodium falciparum malaria, Comoros archipelago and Marseille, France
| Characteristic | Grande Comore | Moheli | Anjouan | Mayotte | Marseille |
|---|---|---|---|---|---|
| Area, km2 | 1,148 | 290 | 424 | 374 | |
| Total population | 330,000 | 40,000 | 280,000 | 190,000 | 50,000–80,000 |
| No. bites by infected mosquitoes/person* | 10–20/y (up to 200/y) | 10/y (up to 1/night) | No data | Low | None |
| Endemicity*† | Mesoendemic to hyperendemic | Mesoendemic to hyperendemic | Mesoendemic to hyperendemic | Hypoendemic | None |
| Total no. reported cases (% confirmed cases), 2006* | 51,148 (34) | 7,866 (27) | 15,408 (19) | 496 (100) | 84 (100) |
| Incidence/1,000 inhabitants, 2006* | 150 | 150 | 50 | 3 | Null |
| % | 96 | 96 | 96 | 90 | 97 |
| Period of sampling, 2007 | Apr–May | Apr–May | Apr–May | Entire year | Entire year |
| No. patients sampled, 2007 | 62 | 61 | 63 | 227 | 111 |
| Median age of sampled patients, y (IQR) ‡ | 4 (2–14.8) | 7.5 (2.6–21) | 7 (3.3–18) | 19 (15–25) | 33 (9.8–40) |
| No. sampled patients in site (A) with history of recent arrival from another site (B) | 7 | 17 | 6 | 13 | 111§ |
| Anjouan | 6 | 9 | – | 7 | |
| Grande Comore | – | 8 | 5 | 6 | |
| Mayotte | 1 | 1 | 0 | – | |
| Moheli | 0 | – | 2 | 0 |
|
| No. randomly genotyped isolates | 36 | 36 | 36 | 36 | 36 |
*Data from World Malaria Report 2008 () and from various Comorian and French official reports and references published in French, all reviewed by the first author in a recent, unpublished thesis (Rebaudet S. Molecular epidemiology and population genetics study of Plasmodium falciparum in Comoros archipelago. Impacts on malaria control [thesis] [in French]. Marseille (France): Université de la Méditerranée; 2009). Cases for Marseille represent those in persons with history of recent arrival from one of the 4 islands. †Malaria endemicity levels based on 2–9 years of available parasite prevalence data, according to the World Health Organization classification: hypoendemic, 0–10%; mesoendemic, 11%–50%; hyperendemic, 51%–75%; and holoendemic, >75% (). ‡IQR, interquartile range. §Mainly from Grande Comore (S. Rebaudet, pers. comm.).
Primer sequences and amplification conditions of the 6 microsatellite loci and Pfcrt, Pfdhfr, and Pfdhps genes of Plasmodium falciparum*
| Loci | GenBank accession no. | Size, bp | Hr | Primer ID | Primer sequences for first and second rounds of nested PCR (5′ → 3′) | Ta, °C |
|---|---|---|---|---|---|---|
| Pf2689 | G37854 | 86 | 2 | Pf2689 PCR1 | TTA ACC TTA TAG CTT CAG AG | 56 |
| TCT TCT TCA CTT ACA TTA AAG | ||||||
| Pf2689 PCR2 | TAT GCA CAC ACG TTT CTA | 54 | ||||
| 6-FAM—CTC CAA GGC ATT CAC GTA | ||||||
| 7A11 | G38831 | 92 | 7 | 7A11 PCR1 | ACA TAT TAT TTC TTC GTA A | 53 |
| TTA TCT CTT CTC TGA GTA A | ||||||
| 7A11 PCR2 | ATG TGT AAG GAG ATA GTA TA | 54 | ||||
| 6-FAM—CAA CTT TCT CTT TTT AAA TAT TAC | ||||||
| C4M79 | G42726 | 220 | 3 | C4M69 PCR1 | TTT TGT AGG AAC ATG TAA | 53 |
| GGA GAC TAG CTC TAC AAT A | ||||||
| C4M69 PCR2 | TTT ATA TCA AGA ATG ACA ACC | 57 | ||||
| NED—TAG CAA CAA TAA ACA ATA TGG | ||||||
| Pf2802 | G37818 | 136 | 5 | Pf2802 PCR1 | GAT GCT TAG TTT AAT CTT ATA ACA AAT A | 60 |
| GAC TTA CTT TCT TAC ATA AAA TCA TTA AC | ||||||
| Pf2802 PCR2 | GTA TAA AAG GAA ATA CCT A | 52 | ||||
| NED—CAG ACT ATC TTA AGG GAA | ||||||
| TRAP | G37858 | 134 | 3 | TRAP PCR1 | ATA AAA CAA ATT ACC GAG TA | 56 |
| ACA ATT CAG ATT ACC TGA A | ||||||
| TRAP PCR2 | CAT AAT AGT AGC AAG AGA | 49 | ||||
| PET—GAT TAT ATA TAG CGA TTT AC | ||||||
| C4M69 | G37956 | 362 | 4 | C4M69 PCR1 | AGA AAT GGA GAT AAA CTA TTA CAA CTA | 60 |
| AGC GCA CGA GAA CAA TC | ||||||
| C4M69 PCR2 | GAA ATG GAG ATA AAC TAT TAC | 61 | ||||
| VIC—AAT TAC ACA ACA GAT GTG AA | ||||||
| Pfcrt | 7 | Pfcrt PCR1 | GTT CTT GTC TTG GTA AAT GT | 50 then 45 | ||
| CCA ATT TTG TTT AAA GTT CT | ||||||
| Pfcrt PCR2 | GTT CTT GTC TTG GTA AAT GT | 50 then 45 | ||||
| 6-FAM—TAA ATG TGC TCA TGT GTTTA | ||||||
| Pfdhfr | 4 | Pfdhfr primers (template) | ||||
| dhfr PCR1 | TTC TCC TTT TTA TGA TGG AAC AAG T | 56 | ||||
| ATA TTT GAA AAT CAT TTG GAT GTA TAG | ||||||
| dhfr PCR2 | ACG TTT TCG ATA TTT ATG C | 47 | ||||
| TCA CAT TCA TAT GTA CTA TTT ATT C | ||||||
| Pfdhfr primers (SNaPshot) | ||||||
| dhfr51-f | AGG AGT ATT ACC ATG GAA ATG TA | |||||
| dhfr16-r | gactgactCTC ATT TTT GCT TTC A AC CTT ACA ACA T | |||||
| dhfr108-f | gactgactACA AAA TGT TGT AGT TAT GGG AAG AAC AA | |||||
| dhfr164-r | ctgactgactgactgactAAT TCT TGA TAA ACA ACG GAA CCT CCT A | |||||
| dhfr59-r | ctgactgactgactgactgactTGA TTC ATT CAC ATA TGT TGT AAC TGC AC | |||||
| Pfdhps | 8 | Pfdhps primers (template) | ||||
| dhps PCR1 | GATTCTTTTTCAGATGGAGG | 52 | ||||
| TTCCTCATGTAATTCATCTGA | ||||||
| dhps PCR2 | GTT GAA CCT AAA CGT GCT GT | 49 | ||||
| TTC ATC ATG TAA TTT TTG TTG TG | ||||||
| Pfdhps primers (SNaPshot) | ||||||
| dhps613-r | TTG ATC ATT CAT GCA ATG GG | |||||
| dhps540-f | gactGAG GAA ATC CAC ATA CAA TGG AT | |||||
| dhps581-r | TAA GAG TTT AAT AGA TTG ATC ATG TTT CTT C | |||||
| dhps436(1)-r | gactgactAGT GTT ATA GAT ATA GGT GGA GAA TCC | |||||
| dhps436(2)-r | gactgactgactgactTGG ATT AGG TAT AAC AAA AAG GAI CA | |||||
| dhps437-r | gactgactgactgactgactTTT TTG GAT TAG GTA TAA CAA AAG GA | |||||
*Size in basepairs for 3D7 clone. Pfcrt, P. falciparum chloroquine resistance transporter; Pfdhpr, P. falciparum dihydrofolate reductase; Pfdhps, P. falciparum dihydropteroate synthase; Chr, chromosome. Primer sequences are given for reactions no. 1 (first round) and no. 2 (second round) of the nested PCRs and are 5′ → 3′ with fluorescent label (VIC, NED, 6-FAM or PET) and annealing temperature (Ta, °C). Thermocycling performed in a Biometra (Goettingen, Germany) 96-well T3 thermocycler.
Genotyping results of the 5 sites studied for Plasmodium falciparum malaria, Comoros archipelago and Marseille, France
| Characteristic | Grande Comore | Moheli | Anjouan | Mayotte | Marseille | Total |
|---|---|---|---|---|---|---|
| No. randomly genotyped isolates | 36 | 36 | 36 | 36 | 36 | 180 |
| No. detected parasites | 50 | 53 | 76 | 44 | 58 | 281 |
| No. single or main clones successfully genotyped | 28 | 20 | 29 | 36 | 36 | 149 |
| No. reconstructed multilocus genotypes | 30 | 24 | 40 | 37 | 39 | 170 |
| No. multi-infected isolates | 9 | 10 | 22 | 4 | 14 | 59 |
MOIs of Plasmodium falciparum infections for the 5 sites studied, Comoros archipelago and Marseille, France*
| Locus | Grande Comore |
| Moheli |
| Anjouan |
| Mayotte |
| Marseille | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | MOI | No. | MOI | No. | MOI | No. | MOI | No. | MOI | |||||
| All 6 loci | 36 | 1.39 |
| 36 | 1.47 |
| 36 | 2.11 |
| 36 | 1.22 |
| 36 | 1.64 |
|
| 34 | 1.03 | 27 | 1.07 | 36 | 1.19 | 36 | 1.08 | 36 | 1.22 | ||||
|
| 34 | 1.12 | 32 | 1.19 | 35 | 1.37 | 36 | 1.14 | 36 | 1.39 | ||||
|
| 34 | 1.21 | 25 | 1.32 | 33 | 1.55 | 36 | 1.11 | 36 | 1.42 | ||||
|
| 31 | 1.00 | 23 | 1.00 | 32 | 1.00 | 36 | 1.00 | 36 | 1.00 | ||||
|
| 35 | 1.42 | 29 | 1.14 | 36 | 1.67 | 36 | 1.08 | 36 | 1.19 | ||||
|
| 32 | 1.06 |
| 21 | 1.19 |
| 34 | 1.12 |
| 36 | 1.03 |
| 36 | 1.11 |
| Mean no. alleles per locus | 8.5 | 8 | 8.5 | 4.5 | 7.8 | |||||||||
*Based on no. multi-infected isolates as shown in Table 2. MOI, multiplicity of infection (no. multi-infected isolates/no. randomly genotyped isolates); no., no. randomly genotyped isolates.
Genetic diversity of Plasmodium falciparum at the 5 sites studied, Comoros archipelago and Marseille, France*
| Locus | Grande Comore | Moheli | Anjouan | Mayotte | Marseille | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. |
| No. |
| No. |
| No. |
| No. |
| |||||
| All 6 loci | 50 | 0.63 |
| 53 | 0.71 |
| 76 | 0.71 |
| 44 | 0.51 |
| 58 | 0.63 |
|
| 35 | 0.47 | 29 | 0.44 | 43 | 0.52 | 39 | 0.15 | 42 | 0.53 | ||||
|
| 38 | 0.81 | 38 | 0.85 | 48 | 0.82 | 41 | 0.41 | 50 | 0.87 | ||||
|
| 41 | 0.86 | 33 | 0.85 | 51 | 0.83 | 40 | 0.74 | 51 | 0.87 | ||||
|
| 31 | 0.00 | 23 | 0.48 | 32 | 0.43 | 36 | 0.48 | 36 | 0.20 | ||||
|
| 39 | 0.79 | 33 | 0.80 | 57 | 0.85 | 39 | 0.60 | 43 | 0.56 | ||||
|
| 34 | 0.87 | 25 | 0.82 | 38 | 0.84 | 37 | 0.68 | 40 | 0.77 | ||||
*No., no. detected parasites. H, Nei unbiased expected heterozygosity index.
Figure 1Results of canonical correspondence analysis (CCA) of Plasmodium falciparum populations from the islands of Grande Comore (GC), Moheli (MOH), Anjouan (ANJ), and Mayotte (MAY) and from Marseille, France (MARS), according to 6 microsatellite loci. CCA is used as a 2-dimensional representation of genetic distance between plasmodial populations assessed from 6 microsatellite loci (Pf2689, C4M79, Pf2802, 7A11, TRAP, and C4M69). This representation requires the projection of data from 6-dimensional space to 2-dimensional space. Canonical axes I and II of the new 2-dimensional space are calculated to conserve the highest genetic variance between populations after projection of data, and their significance was tested by Monte Carlo permutation that also enabled estimation of the 95% confidence intervals (ellipses) of the centroid (dots) of each population.
Figure 2Genetic differentiation (Fst) between Plasmodium falciparum populations from the islands of Grande Comore (GC), Moheli (MOH), Anjouan (ANJ), and Mayotte (MAY) and from Marseille, France (MARS), according to 6 microsatellite loci. Pairwise comparison among sites that used complete dataset (n = 281) and 6 microsatellite loci (Pf2689, C4M79, Pf2802, 7A11, TRAP, and C4M69). Departure of F from 0 tested after 10,000 bootstrap simulations and by using Bonferroni corrected p values obtained after 200 permutations. Difference is significant if adjusted p<0.005. Black arrows indicate negligible (F<0.01) and nonsignificant differentiation. Asterisks (*) and orange arrows indicate moderate (0.01
Figure 3Relationship between geographic and genetic distances for each pair of Comoros islands (top) and between mean percentage of travelers among sampled patients and genetic distance for each pair of Comoros islands (bottom). Genetic distances were calculated as (F/1 – F ), where F is the Wright F statistic. Mean percentage of travelers was calculated from the total number of sampled patients in one site (NA) with history of recent arrival from another site (NB) by using the equation ([NB→A/NA] + [NA→B/NB])/2; data in Table 1. GC, Grande Comore; MOH, Moheli; ANJ, Anjouan; MAY, Mayotte; Ln, logarithmically transformed.
Frequency of chemoresistance-associated point mutations of 5 sites studied for Plasmodium falciparum malaria, Comoros archipelago and Marseille, France*
| Locus | No. isolates (% mutations) | ||||
|---|---|---|---|---|---|
| Grande Comore | Moheli | Anjouan | Mayotte | Marseille | |
|
| |||||
| 76T | 33 (45.5) | 33 (45.5) | 36 (13.9) | 36 (91.7) | 36 (52.8) |
| 76 T and K | 33 (9.1) | 33 (6.1) | 36 (5.6) | 36 (2.8) | 36 (0) |
| K76 (Wt) | 33 (45.5) | 33 (48.5) | 36 (80.6) | 36 (5.6) | 36 (47.2) |
|
| |||||
| 108N | 26 (50.0) | 19 (84.2) | 34 (38.2) | 36 (50.0) | 36 (80.6) |
| 108 N and S | 26 (15.4) | 19 (5.3) | 34 (11.8) | 36 (0) | 36 (2.8) |
| S108 (Wt) | 26 (34.6) | 19 (10.5) | 34 (50.0) | 36 (50.0) | 36 (16.7) |
| 59R | 26 (50.0) | 19 (78.9) | 34 (26.5) | 36 (44.4) | 36 (77.8) |
| 59 R and C | 26 (7.7) | 19 (10.5) | 34 (11.8) | 36 (0) | 36 (2.8) |
| C59 (Wt) | 26 (42.3) | 19 (10.5) | 34 (61.8) | 36 (55.6) | 36 (19.4) |
| 51I | 26 (38.5) | 19 (63.2) | 34 (23.5) | 36 (44.4) | 35 (65.7) |
| 51 I and N | 26 (11.5) | 19 (5.3) | 34 (2.9) | 36 (0) | 35 (2.9) |
| N51 (Wt) | 26 (50.0) | 19 (31.6) | 34 (73.5) | 36 (55.6) | 35 (31.4) |
| 108N and 59R | 26 (57.7) | 19 (89.5) | 34 (38.2) | 36 (44.4) | 36 (80.6) |
| 108N and 59R and 51I | 26 (50.0) | 19 (68.4) | 34 (26.5) | 36 (44.4) | 35 (68.6) |
|
| |||||
| 437G | 25 (4.0) | 24 (20.8) | 31 (0) | 36 (0) | 36 (8.3) |
| 437 G and A | 25 (0) | 24 (4.2) | 31 (0) | 36 (0) | 36 (5.6) |
| A437 (Wt) | 25 (96.0) | 24 (75.0) | 31 (100.0) | 36 (100.0) | 36 (86.1) |
| 540E | 25 (0) | 24 (4.2) | 31 (0) | 36 (0) | 36 (0) |
| 540 E and K | 25 (4.0) | 24 (0) | 31 (0) | 36 (0) | 36 (0) |
| K540 (Wt) | 25 (96.0) | 24 (95.8) | 31 (100.0) | 36 (100.0) | 36 (100.0) |
| 437G and 540E | 25 (0) | 24 (0) | 31 (0) | 36 (0) | 36 (0) |
*Pfcrt, P. falciparum chloroquine resistance transporter; Pfdhpr, P. falciparum dihydrofolate reductase; Pfdhps, P. falciparum dihydropteroate synthase.